Tucson, Arizona (PRWEB) April 27, 2015
Faxitron® Bioptics, LLC and Cokiya, Inc. are pleased to announce the appointment of Faxitron as the exclusive worldwide distributor of Cokiya’s groundbreaking single-use surgical gamma probe, TruNode™. This device is the culmination of many years of dedicated work by the Cokiya team, whose mission has been to develop and commercialize a high performance, cost effective, wireless, single-use gamma probe.
Gamma probes are routinely used intraoperatively for sentinel lymph node mapping with breast cancer and melanoma, for parathyroid surgery, and for radioactive seed localization. Although wireless technology is now common in gamma probes, reusable probes must be draped for sterility prior to every use and since they are not tethered, tend to be accidentally disposed of requiring expensive replacement. TruNode™ addresses both these concerns in that it is the first cost effective, single-use gamma probe that is fully sterile. New policies requiring fully sterile probes for infection control and patient safety are being implemented in numerous countries around the world.
In addition to being sterile and single use, TruNode™ delivers superior performance. It is optimized for the most common radio-guided surgical procedures with best-in-class 10% energy resolution, three modes of detection and a small operative element. This makes detecting faint nodes close to the injection site easier and allows for use in the smallest incisions, as well as for radioactive seed localization.
Other key features of the TruNode™ include:
- Simple to use finger-tip control from the sterile field, including switching between high-sensitivity ‘scan’, high-resolution ‘point’ and I-125 ‘seed’ modes
- Proprietary heuristic audio feedback for elucidating hotspots more clearly
- Voice reporting of count-rate minimizes need to view display
- Compact User Feedback Unit (UFU) is rechargeable and mounts to IV pole eliminating its footprint in the space conscious O.R.
“Faxitron could not be more excited about our new partnership with Cokiya,” said Faxitron CFO & COO, Donogh O’Driscoll. “TruNode™ is a game changer in that it immediately broadens the accessibility of gamma probe technology to a very large portion of the market hereto unable to afford existing non-disposable capital equipment alternatives.” He added,”We are expanding our sales and clinical applications teams to support our market development program both in the United States and in the 45 countries where we have distribution. TruNode™ is a perfect complement to our market leading BioVision Specimen Radiography imaging system.”
Commenting on their new partnership with Faxitron, Cokiya President & CEO Richard Conwell said, “In Faxitron, the Cokiya team has found a likeminded partner. Faxitron has proven itself to be a nimble operator capable of thoughtfully growing markets from the ground up. Together we share a passion for bringing life-saving technology to those most in need of it as efficiently as possible. We look forward to building something special together.”
To learn more about TruNode™, please visit http://www.faxitron.com/TruNode
About Faxitron® Bioptics, LLC
Faxitron is the world’s largest and only fully vertically integrated, dedicated cabinet x-ray company. With an installed base of over 7,000 systems in medical facilities and scientific and industrial research laboratories around the globe, Faxitron is the pioneer and industry standard in cabinet x- ray systems for specimen radiography, research, and NDT applications. For more than 40 years, Faxitron has defined cabinet x-ray by developing x-ray sensor technology and innovative systems to meet the evolving needs of our customers. To learn more about Faxitron, please visit http://www.faxitron.com
About Cokiya, Inc.
Cokiya is a medical device company focusing on low cost, wireless, disposable sensors for monitoring physiological parameters and surgical guidance. The company’s flagship product, the TruNode™ gamma probe, is the first commercially-available single-use surgical probe for sentinel node, parathyroid, and radioactive seed localization procedures. Cokiya’s principals have successfully co-founded three prior companies and collectively have over 50 years’ experience in medical device development and commercialization. To learn more about Cokiya, please visit http://www.cokiyainc.com